Mammary gland condition in premenopausal women with endometrial hyperplasia

Yu.E. Dobrokhotova, М.Р. Нариманова, L.V. Saprykina, I.Yu. Ilina, M. L. Mazo
In: Meditsinskiy sovet = Medical Council · 2021 · pp. 120–127 · doi:10.21518/2079-701x-2021-3-120-127 · W3153454885
article OA: diamond CC0 ⤵ 1 in-corpus citation
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study investigated the effects of indole-3-carbinol (I3C) therapy on mammary gland conditions in premenopausal women with endometrial hyperplasia, finding improvements in mastalgia, ultrasound, and mammography findings after 12 months.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 ⓘ

This prospective study evaluated breast gland status in 42 premenopausal women aged 45–52 with endometrial hyperplasia, using clinical assessment, ultrasound, mammography with BI-RADS, and cytology of nipple discharge before treatment and after 6 and 12 months of indole-3-carbinol (I3C) 400 mg/day. All participants had mastalgia at baseline, and BI-RADS categories indicating benign findings (predominantly BI-RADS 2) were much more frequent than BI-RADS 1 at entry, with subsequent improvements over time: pain resolved in 59.5% by 6 months and reductions in OНЕ1/16a-ОНЕ1 deviations and higher proportions of BI-RADS improvements were reported by both 6 and 12 months. The paper explicitly frames I3C as effective and safe for dysplastic benign breast conditions, with conclusions limited by reliance on descriptive statistics and the single-arm, noncomparative design. Relevance to endometriosis: the introduction situates this study within a broader context of dys-hormonal gynecologic disorders associated with benign breast changes, explicitly listing “outer or internal endometriosis” among those conditions, though the main study focus is breast findings in endometrial hyperplasia under I3C therapy rather than endometriosis itself.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Introduction. Amidst a steady increase in hyperplastic processes in uterus and mammary glands, numerous studies have shown that women with dyshormonal pathology of mammary glands had a range of gynecological diseases: external or internal endometriosis, hyperplastic processes of the endometrium and myometrium, polyps, polycystic ovary syndrome (PCOS), etc. Objective. To assess the mammary gland condition in premenopausal women with endometrial hyperplasia during indole-3-car-binol (I3C) therapy. Materials and methods. A total of 42 premenopausal patients aged 45-52 years (48.54 ± 1.83) were enrolled in an open-label prospective study. All patients received I3C 400 mg a day for 12 months. The examination included clinical laboratory, ultrasound imaging and mammographic examination of the mammary glands, cytologic examination of a nipple discharge. The examinations were carried out at the baseline, 6 and 12 months after starting treatment. The study findings were evaluated using descriptive statistics. Differences were considered significant at p <0.05. Results and discussion . All patients were diagnosed as having mastalgia before starting treatment. Mammary gland ultrasound imaging showed that the frequency of BI-RADS 2 was 9.5 times higher than that of BI-RADS 1 (90.5% and 9.5%, respectively, p <0.05). Mammography revealed that the frequency of BI-RADS 2 was 9.26 times higher than that of BI-RADS 1 (88% and 9.5%, respectively, p <0.05). After 6-month therapy, 59.5% of patients reported the disappearance of pain syndrome, the number of patients with ONE1/16a-ONE1 deviations decreased by 22%, 7.1% of patients showed improvement of ultrasound picture in BI-RADS. After 12-month therapy, the number of patients with ONE1 / 16a-ONE1 deviations decreased by 92.86% compared with the figures before starting treatment, ultrasound imaging showed improvement in the BI-RADS picture in 19% of patients, mammography findings - in 28.5% of patients. I3C is an effective and safe method to treat benign breast diseases in premenopausal women. Conclusion . Indole-3-carbinol therapy can be assessed as the treatment having an influence on the general components of pathogenesis of endometrial hyperplasia and benign hyperplastic processes in mammary glands. It is advisable to consider the use of indole-3-carbinol combined with antioxidant resveratrol in clinical practice.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

References (23)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK